Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy
- Hernando Cubero, J. 1
- Grande, E. 2
- Jimenez Fonseca, P. 3
- Villabona, C. 4
- Trigo Perez, J.M. 5
- Martinez Trufero, J. 6
- Pajares Bernad, I. 6
- Lopez, C. 7
- Alonso, T. 8
- Biarnes, J. 9
- RamónY Cajal, T. 10
- Duran, M. 11
- Grau, J.J. 12
- Arevalo Lobera, S. 13
- Mesia Nin, R. 14
- Llanos, M. 15
- Dalmau Portulas, E. 16
- Alvarez, C. 17
- Zafon, C. 1
- Capdevila, J. 1
-
1
Hospital Vall d'Hebron
info
- 2 Head of Medical Oncology Department, MD Anderson Cancer Center Center Espana
-
3
Hospital Universitario Central de Asturias
info
-
4
Hospital Universitari de Bellvitge
info
-
5
Hospital Universitario Virgen de la Victoria
info
-
6
Hospital Miguel Servet
info
-
7
Hospital Universitario Marqués de Valdecilla
info
-
8
Hospital Ramón y Cajal
info
-
9
Hospital Universitari de Girona Dr. Josep Trueta
info
-
10
Hospital de la Santa Creu i Sant Pau
info
- 11 Medical Oncology, Hospital Universitario Rey Juan Carlos
-
12
Hospital Clinic Barcelona
info
-
13
Hospital Universitario de Donostia
info
-
14
Hospital Universitari Germans Trias i Pujol
info
-
15
Hospital Universitario de Canarias
info
-
16
Hospital de Sabadell
info
-
17
Hospital Universitario La Paz
info
Journal:
Annals of oncology : official journal of the European Society for Medical Oncology
ISSN: 1569-8041
Year of publication: 2018
Volume: 29
Pages: viii476
Type: Article
DOI:
10.1093/annonc/mdy293.022
PMID:
32137225
SCOPUS:
2-s2.0-85081528644
GOOGLE SCHOLAR
lock_openOpen access editor
Data source: Scopus